Neurobiology of cannabis addiction

Indian Journal of Physiology and Pharmacology

Volumn 52, Issue 3, 2008, Pages 217-232

  Jain, Raka ^a   Balhara, Yatan Pal Singh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anandamide; Cannabinoids; Cannabis; Receptors

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; STREET DRUG;

ANIMAL; BRAIN; CANNABIS ADDICTION; DRUG EFFECT; DRUG TOLERANCE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; REWARD;

ANIMALS; BRAIN; CANNABINOIDS; DRUG TOLERANCE; HUMANS; MARIJUANA ABUSE; RECEPTORS, CANNABINOID; REWARD; STREET DRUGS;

EID: 67651163533     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. 1-tetrahydrocannabinol and other cacabinoids with emphasis on man. Pharmacol Rev 1986; 38: 21-43.
2. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178: 101-106.
3. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-360.
4. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005; 168: 657-690.
5. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005: 10: 15A-22A.
6. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 2006; 28: 447-453.
7. 9-tetrahydrocannabinol (THC). Chem Biodivers 2007; 4: 1664-1677.
8. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 293-294.
9. Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W. Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 2007; 46: 408-417.
10. Dannon PN, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol 2004; 19: 97-101.
11. Zvolensky MJ, Bernstein A, Sachs-Ericsson N, Schmidt NB, Buckner JD, Bonn-Miller MO. Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample. J Psychiatr Res 2006; 40: 477-486.
12. Matsuda LA, Lolait SJ, Brownstein MJ, et al. 'Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
13. Munro S, Thomas KL, Abu SM. Molecular characterization of a peripheral receptor for cannabinoides. Nature 1993: 365: 61-65.
14. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-1270.
15. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
16. Mechoulam R, Parker MR, et al. Cannabis and alcohol- a close friendship. Trends Pharmacol 2003; 24: 266-268.
17. Rinaldi-Carmona M, Barth F, Heaulme M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-244.
18. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48: 443-450.
19. 9-tetrahydrocannabinol). Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 721-730.
20. Devane WA, Dysarz FA 3rd, Johnson MR., et al. Determination and characterization a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 3: 605-613.
21. Herkenham M, Lynn AB, Johnson MR, et al. Characterization and localization of cannabinoid receptor in the rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-583.
22. Kessler R, Mcgonagle K, Zha O, et al. Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
23. Tsou K, Brown S, Sanudo-pena MC, et al. Immunohistochemical distribution of cannabinoid receptors in rat central nervous system. Neuroscience 1998; 83: 393-411.
24. Jansen EM, Haycock DA, Ward SJ, et al. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 1992; 575: 93-102.
25. Glass M, Dragunow M, Paul RLM. Cannabinoid receptors in the human brain; a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77: 99-318.
26. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 51-178.
27. Palmer SL, Khanolkar AD, Makriyannis A. Natural and synthetic endocannabinoids and their structure activity relationship. Curr Pharm 1998; 6: 1381-1397.
28. Navarro M, Hernandez E, Munoz RM, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491-496.
29. Lagalwar S, Bordayo EZ, Hoffinan KL, et al. Anandamides inhibit binding to the muscarinic acetycholine receptor. J Mol Neuroscience 1999; 13: 55-61.
30. Volfe Z, Dvilansky A, Nathan I. Cannabinnoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol 1998; 5: 243-246.
31. 9-tetrahydrocannabinol induced arachidonic acid release and secretagogue evoked phosphoinositide breakdown and Ca+2 mobilisation of exogenous pancreas. Mol Pharmacol 1998; 34: 543-548.
32. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association. Br J Psychiatry 1999; 157: 25-33.
33. Costentin J. Neurobiology of cannabis-recent data enlightening driving disturbances. Ann Pharm Fr 2006; 64: 148-159.
34. Haney M, Ward A, Comer SD, et al. Abstinence symptoms following smoked marijuana in humans. Psychopharmacolosy (Berl) 1999; 141: 395-404.
35. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-122.
36. Kuster JE, Stevenson JI, Ward SJ, et al. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 1993; 264: 1352-1362.
37. Wegner T, Moldrich G, Furst S. Neuromorphological background of cannabis addiction. Brain Res Bul 2003; 61: 125-128.
38. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001: 22: 565-572.
39. Maldonado R, Rodriguez De Fonseca. Cannabinoid Addiction: Behavioral models and correlates. Neurosci 2002; 22: 3326-3331.
40. 9-tetrahydrocannabinol treated mice. Behav Brain Res 2006; 173: 255-261.
41. Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005; 168: 691-717.
42. Manzanares J, Urig Ãen L, Rubio G, Palomo T. Role of endocannabinoid system in mental diseases. Neurotox Res 2004; 6: 213-224.
43. 9-tetrahydrocannabinol-tolerant rats. Psychopharmacology (Berl) 1977; 55: 243-249.
44. Hine B, Friedman E, Torrelio M., et al. Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 1975; 187: 443-445.
45. Hohmann AJ, Martin WJ, Tsou K, et al. Inhibition of noxious stimulus-evoked activity of spinal cord dorsalhorn neurons by the cannabinoid WIN 55, 212-2. Life Sci 1995; 56: 2111-2118.
46. Pontieri FE, Monnazzi P, Scontrini A., et al. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. Eur J Pharmacol 2001; 421: R1-R3.
47. 9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neuroscience 2001; 13: 1816-1824.
48. Ledent C, Valverde O, Cossu G., et al. J Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-404.
49. 9-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 2001; 298: 1007-1014.
50. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 1991; 40: 581-585.
51. 9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol Biochem Behav 1991; 40: 593-598.
52. 9-tetrahydrocannabinol extracellular acetylcholine concentration and alteration performance in the T-maze. Neuropharmacology 2001; 41: 392-399.
53. 9-tetra hydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol Brain Res 1997; 46: 100-108.
54. Rubino T, Massi P, Patrini G, et al. Chronic CP-55, 940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 1994; 5: 2493-2496.
55. Zhuang S, Kittler J, Grigorenko EV, et al. Effects of long-term exposure to THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 1998; 62: 141-149.
56. Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005; 168: 691-717.
57. Oveido A, Glowa J, Herkenham, M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993; 616: 293-302.
58. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 1995; 51: 731-737.
59. 35S] autoradiography in rat brain. J Neuroscience 1996; 16: 8057-8066.
60. Rubino T, Patrini G, Massi P, et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998; 285: 813-819.
61. Martellotta MC, Cossu G, Fattore L, et al. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 1998; 85: 327-330.
62. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 2002; 95: 153-164.
63. Nocon A, Wittchen HU, Pfister H, Zimmermann P, Lieb R. Dependence symptoms in young cannabis users? A prospective epidemiological study. J Psychiatr Res 2006; 40: 394-403.
64. 9-tetrahydrocannabinol in rats. Nippon Yakurigaku Zasshi 2001; 117: 35-41.
65. Mcgee R, Williams S, Poulton R. et al. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction 2000; 95: 491-503.
66. Jones RT, Benowitz NL, Herning RL. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21: 143S-152S.
67. Rosenkrantz H. Cannabis, marihuana, and cannabinoid toxicological manifestations in man and animals. In: Cannabis and Health Hazards: Proceedings of an ARF/WHO Scientific meeting on Adverse Health and Behavioral Consequences of Cannabis use. Fehr KO, Kalant H, (Eds). Toronto: Addiction Research Foundation 1983; 91-175.
68. Farrell M, Howes S, Taylor C, et al. Substance misuse and psychiatric comorbidity: an overview of the OPCS national psychiatric morbidity. Addict Behav 1998; 23: 908-918.
69. Schutz CG, Chilcoat HD, Anthony JC. The association between sniffing inhalants and injecting drugs. Compr Psychiatry 1994; 35: 99-105.
70. Goddard IW. Drug addiction: Marijuana: harder than thought? Science 1997; 276: 2048-2054.
71. Ramos JA, González S, Sagredo O, Gómez-Ruiz M, Fernández-Ruiz J. Therapeutic potential of the endocannabinoid system in the brain. Mini Rev Med Chem 2005; 5: 609-617.